Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.32
- Piotroski Score 3.00
- Grade Buy
- Symbol (CMPS)
- Company COMPASS Pathways plc
- Price $6.82
- Changes Percentage (-1.3%)
- Change -$0.09
- Day Low $6.74
- Day High $7.08
- Year High $12.75
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $23.00
- High Stock Price Target $23.00
- Low Stock Price Target $23.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.30
- Trailing P/E Ratio -3.02
- Forward P/E Ratio -3.02
- P/E Growth -3.02
- Net Income $-118,923,174